Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.65 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.44 |
| ▸ | TTR known ✓ | P02766 | 2/20 | 0.41 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.41 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 5/20 | 0.65 |
| ▸ | CA1 | P00915 | 5/20 | 0.65 |
| ▸ | CA9 | Q16790 | 5/20 | 0.65 |
| ▸ | CA7 | P43166 | 4/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.65 |
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | DDO | Q99489 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 4/20 | 0.45 |
| ▸ | CA5A | P35218 | 4/20 | 0.44 |
| ▸ | CA3 | P07451 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571808 | 0.98 | CA12 (0.68) | CA12CA1CA2CA9CA7 | |
| SCHEMBL29581511 | 0.98 | CA12 (0.68) | CA12CA1CA2CA9CA7 | |
| Hydrochloric Acid SCHEMBL2810739 | 0.85 | KDM4E (0.54) | CA12CA1CA2CA9CA7 | |
| Hydrochloric Acid SCHEMBL9311860 | 0.85 | KDM4E (0.54) | CA12CA1CA2CA9CA7 | |
| Hydrochloric Acid SCHEMBL8653192 | 0.85 | KDM4E (0.54) | CA12CA1CA2CA9CA7 | |
| Hydrochloric Acid SCHEMBL4295557 | 0.85 | KDM4E (0.54) | CA12CA1CA2CA9CA7 | |
| Hydrochloric Acid SCHEMBL28553805 | 0.83 | CA12 (0.83) | CA12CA1CA2CA9CA7 | |
| 3,5-Dihydroxybenzoic Acid SCHEMBL5695849 | 0.83 | CA12 (0.94) | CA12CA1CA2CA9CA7 | |
| SCHEMBL2820215 | 0.83 | KDM4E (0.56) | CA12CA1CA2CA9CA7 | |
| SCHEMBL223304 | 0.83 | KDM4E (0.56) | CA12CA1CA2CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4733297-A1 | INTEGRIN-INHIBITING SMALL MOLECULE COMPOUND | Antibody Therapeutics, Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024262620-A1 | INTEGRIN-INHIBITING SMALL MOLECULE COMPOUND | 株式会社抗体医学研究所 | 2024-12-26 | — | — | WO | disclosed |
| WO-2024196853-A1 | SUBSTITUTED CYCLOHEXENE AND CYCLOHEXANE INHIBITORS OF ORNITHINE AMINOTRANSFERASE | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-07-12 | — | — | US | disclosed |
| WO-2011081280-A2 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2011-07-07 | — | — | WO | disclosed |
| US-5656636-A | TREATING PSORIASIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5633258-A | Pyridine compounds for treating leukotriene-related diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| US-5631262-A | Pyridine compounds for treating leukotriene-related diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-20 | — | — | US | disclosed |
| CN-1092409-A | The compound that is used for the treatment of leukotriene-related disease | SMITHKLINE BEECHAM CORP (US) | 1994-09-21 | — | — | CN | disclosed |
| EP-0604529-A1 | PYRIDINE COMPOUNDS FOR TREATING LEUKOTRIENE-RELATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0593464-A1 | BENZOIC ACID DERIVATIVES and their use as LTB4 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1994-04-27 | — | — | EP | disclosed |
| CN-1073431-A | The compound that is used for the treatment of leukotriene-related disease | SMITHRLINE BEECHAM CORP (US) | 1993-06-23 | — | — | CN | disclosed |
| WO-1993006085-A1 | PYRIDINE COMPOUNDS FOR TREATING LEUKOTRIENE-RELATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-01 | — | — | WO | disclosed |
| EP-0593464-A4 | BENZOIC ACID DERIVATIVES. | SMITHKLINE BEECHAM CORP (US) | 1993-02-12 | — | — | EP | disclosed |
| CN-1058015-A | Benzoic acid derivative | SMITHKLINE BEECHAM CORP (US) | 1992-01-22 | — | — | CN | disclosed |
| WO-1991018601-A1 | BENZOIC ACID DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0134782-A1 | PROCESS FOR THE PREPARATION OF 3-AMINO-5-HYDROXYBENZOIC ACIDS AND DERIVATIVES AND ANALOGUES THEREOF | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1985-03-27 | — | — | EP | disclosed |
| EP-0134782-A4 | PROCESS FOR THE PREPARATION OF 3-AMINO-5-HYDROXYBENZOIC ACIDS AND DERIVATIVES AND ANALOGUES THEREOF. | UNIV AUSTRALIAN (AU) | 1985-02-18 | — | — | EP | disclosed |
| WO-1984000750-A1 | PROCESS FOR THE PREPARATION OF 3-AMINO-5-HYDROXYBENZOIC ACIDS AND DERIVATIVES AND ANALOGUES THEREOF | UNIV AUSTRALIAN (AU) | 1984-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | GCK, GCKR, HK1 | CA2 2557/4885DPP4 50/4885TTR 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.